Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
STAT3
REST API REST API
Homo sapiens
STAT3 is differentially expressed in 347 experiments: 133 organism parts: liver, adipose tissue, ... (131 more);, 201 disease states: normal, glioblastoma, ... (199 more);, 107 cell types 473 cell lines 66 compound treatments and 87 other conditions.
Synonyms APRF
Orthologs STAT3 (Bos taurus)   Stat3 (Rattus norvegicus)   stat3 (Danio rerio)   Stat3 (Mus musculus)   STAT3 (Gallus gallus)   stat3.1 (Xenopus laevis)   STAT3 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term regulation of multicellular organism growth, cytosol, plasma membrane, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytokine-mediated signaling pathway, cytoplasm, cellular component movement, cell proliferation, protein import into nucleus, transcription, DNA-dependent, acute-phase response, positive regulation of Notch signaling pathway, transcription from RNA polymerase II promoter, glucose homeostasis, signal transducer activity, transcription factor binding, sequence-specific DNA binding, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, protein kinase binding, nucleus, eye photoreceptor cell differentiation, response to drug, JAK-STAT cascade, nervous system development, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, regulation of transcription from RNA polymerase II promoter, response to ethanol, non-membrane spanning protein tyrosine kinase activity, signal transduction, positive regulation of transcription, DNA-dependent, calcium ion binding, glucocorticoid receptor binding, response to cytokine stimulus, eating behavior, astrocyte differentiation, temperature homeostasis, ligand-regulated transcription factor activity, interspecies interaction between organisms, radial glial cell differentiation, response to peptide hormone stimulus, growth hormone receptor signaling pathway, response to estradiol stimulus, interleukin-6-mediated signaling pathway, sexual reproduction, response to organic substance, nerve growth factor receptor signaling pathway, cellular response to hormone stimulus, JAK-STAT cascade involved in growth hormone signaling pathway, sequence-specific DNA binding transcription factor activity, response to organic cyclic compound, CCR5 chemokine receptor binding, transcription regulatory region DNA binding
InterPro Term SH2, STAT_TF_alpha, STAT_TF_prot_interaction, STAT_TF_DNA-bd
Gene-Disease Assocation HYPER-IgE RECURRENT INFECTION SYNDROME, AUTOSOMAL DOMINANT
UniProt Accession P40763
Search EB-eye ENSG00000168610
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (45 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
A549
2
E-GEOD-3202, E-GEOD-6013
HCC1937
2
E-MTAB-37, E-MTAB-62
HCC1954
2
E-MTAB-37, E-GEOD-29119
KG1
2
E-MTAB-37, E-GEOD-24147
467 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (50 experiments)

Factor Value U/D Experiments
adipocyte
3
E-AFMX-5, E-MTAB-25, E-TABM-145
endothelial cell
3
E-GEOD-19240, E-GEOD-96, E-GEOD-3920
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
partially reprogrammed human induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
breast cancer
1
E-GEOD-29119
cardiac myocyte
1
E-AFMX-5
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (73 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-GEOD-96, E-MTAB-62, E-MTAB-37
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
lung adenocarcinoma
1
3
E-MTAB-37, E-MEXP-231, E-MTAB-62, E-GEOD-2514
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-16728, E-GEOD-20602
chronic myelogenous leukemia
2
E-MTAB-37, E-GEOD-5550
acute promyelocytic leukemia
2
E-GEOD-995, E-GEOD-96
195 more value(s).


Compound treatment

studied in E-GEOD-5542, E-GEOD-5741, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (39 experiments)

Factor Value U/D Experiments
none
7
12
E-GEOD-5542, E-GEOD-5824, E-MEXP-1958, E-TABM-868, E-MEXP-1230, ... (19 experiments)
interferon-gamma
2
E-GEOD-5542, E-GEOD-1432
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
placebo
2
E-MEXP-1335, E-MEXP-1327
unknown
1
E-GEOD-7307
-
1
1
E-MEXP-2645
60 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
48 years
1
1
E-GEOD-4922
48
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-MEXP-1251, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-21612, E-MEXP-2657, E-GEOD-20540, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (36 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-GEOD-17636, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-1880, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10896, E-GEOD-17204

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-1643, E-GEOD-12293, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, ... (8 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561

Tumor size
studied in E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.472 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM